Melanoma Clinical Trials
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Recruiting
- Pancreatic Cancer
- +4 more
- Cyclophosphamide
- +3 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022N
Recruiting
- Melanoma
- Cyclophosphamide
- +4 more
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022N
Suspended
- Melanoma
- Intervention Arm
- Standard diet and exercise
- Loma Linda, California
- +1 more
2022-04-07
Apr 7, 2022P
Recruiting
- Oncology
- +9 more
- E-602
- Pembrolizumab
- Grand Rapids, Michigan
- +2 more
2022-04-07
Apr 7, 2022C
Recruiting
- Melanoma
- +3 more
- Phoenix, Arizona
- +19 more
2022-04-06
Apr 6, 2022C
Recruiting
- Melanoma
- +3 more
- Phoenix, Arizona
- +24 more
2022-04-06
Apr 6, 2022H
Active, not recruiting
- Melanoma
- Beijing City, China
- +2 more
2022-04-07
Apr 7, 2022N
Enrolling by invitation
- Melanoma
- +3 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022N
Enrolling by invitation
- Melanoma
- +4 more
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022N
Active, not recruiting
- Prostate Cancer
- +4 more
- Bethesda, MarylandNational Cancer Institute (NCI), 9000 Rockville Pike
2022-04-07
Apr 7, 2022N
Active, not recruiting
- Retinoblastoma
- +2 more
- Bethesda, MarylandNational Cancer Institute (NCI), 9000 Rockville Pike
2022-04-07
Apr 7, 2022N
Completed
- Gastrointestinal Cancer
- +3 more
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022N
Recruiting
- Xeroderma Pigmentosum
- +4 more
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022M
Active, not recruiting
- Melanoma Stage Iv
- +2 more
- Denosumab
- +2 more
- Albury, New South Wales, Australia
- +9 more
2022-04-06
Apr 6, 2022R
Completed
- Dysplastic Nevus
- +3 more
- Best Practice
- +2 more
- New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
2022-04-05
Apr 5, 2022I
N
Recruiting
- Advanced Malignant Solid Neoplasm
- +49 more
- Adavosertib
- +33 more
- Birmingham, Alabama
- +1423 more
2022-04-06
Apr 6, 2022H
Recruiting
- Gastric Cancer
- +8 more
- Los Angeles, California
- +2 more
2022-04-05
Apr 5, 2022N
N
Recruiting
- Pancreatic Cancer
- +15 more
- NGM831
- NGM831 plus pembrolizumab
- Grand Rapids, Michigan
- +2 more
2022-04-05
Apr 5, 2022M
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma
Active, not recruiting
- Melanoma
- Dabrafenib
- +2 more
- Sydney, New South Wales, Australia
- +2 more
2022-04-04
Apr 4, 2022S
Completed
- Acute Myeloid Leukemia
- +8 more
- DSP-7888 Dosing Emulsion
- Denver, Colorado
- +7 more
2022-04-04
Apr 4, 2022H
Recruiting
- Neoplasms
- +27 more
- Culver City, California
- +29 more
2022-04-05
Apr 5, 2022D
Recruiting
- Liver Metastases
- +10 more
- DNX-2440
- Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute, Inc.
2022-03-28
Mar 28, 2022I
Active, not recruiting
- Non-Small Cell Lung Cancer
- +12 more
- N-803 + Pembrolizumab
- +9 more
- Anchorage, Alaska
- +34 more
2022-04-04
Apr 4, 2022